Volociximab Biosimilar, Human ITGA5 (CD49e)

Size

£544.00

SKU:: 592308
Purity:: ≥95% (reducing SDS-PAGE, HPLC). Endotoxin: ≤1EU/mg (LAL)
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Human
Immunogen:: Recombinant protein corresponding to human integrin α5β1, expressed in CHO cells.
Format:: Supplied as a 0.2uM filtered solution, pH 6.0. No stabilizers or preservatives added.
Extra Details:: Volociximab is a high-affinity IgG4 chimeric (82% human, 18% murine) monoclonal antibody that specifically binds to α5β1 integrin. Integrins are a superfamily of widely expressed transmembrane glycoprotein receptors for extracellular matrix ligands, such as fibronectin, vitronectin, laminin, collagens, and other plasma membrane proteins, and function in the regulation of a broad variety of cellular processes, including embryogenesis, inflammation, bone metabolism, apoptosis, cell proliferation, angiogenesis, and tumor metastasis. Relevant preclinical models for the mechanism of action and antitumor activity evaluation were selected based on the cross-reactivity of volociximab to the non-human α5β1 homologues. Volociximab and its parent mouse antibody, IIA1, do not cross-react with murine α5β1 integrin, but do cross-react and block the chicken and cynomolgus monkey target protein. Volociximab inhibited human umbilical vein endothelial cells from forming tube-like vessel structures in a three-dimensional fibrin matrix in vitro and was independent of the growth factor stimulus. These data suggest that the α5β1 signaling pathways are downstream of growth factor stimulation. Moreover, volociximab inhibited growth factor–stimulated human neonatal foreskin vascular growth when grafted into severe combined immunodeficient mice in vivo. In addition, volociximab inhibited vessel formation and human tumor xenograft growth in the chicken chorioallantoic membrane model in ovo. Finally, in a preclinical model of choroidal neovascularization in cynomolgus monkeys, volociximab was a potent inhibitor of angiogenesis. Applications: Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Volociximab. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Shipping Conditions:: Blue Ice